QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DFTX

QT80Definium Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
24.48
+0.05+0.20%
OverviewShort InterestFilings
DFTXQT80Definium Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
24.48+0.20%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own19.31%
Shs Outstand109.07M
Perf Week1.53%
Market Cap2.66BForward P/E-EPS next Y-1.66Insider Trans-0.08%Shs Float-Perf Month22.28%
Enterprise Value2.43BPEG0.15EPS next Q-0.55Inst Own-Short Float-Perf Quarter31.19%
Income-238249073.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y99.67%
Sales-P/B9.62EPS next Y27.62%ROA-59.19%Short Interest-Perf YTD82.82%
Book/sh1.20P/C-EPS next 5Y-ROE-102.48%52W High26.25 -6.74%Perf Year264.83%
Cash/sh1.92P/FCF-EPS past 3/5Y-ROIC-60.39%52W Low6.35 285.51%Perf 3Y-
Dividend Est.-EV/EBITDA-10.91Sales past 3/5Y-Gross Margin0.00%Volatility3.29% 4.08%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-1566.67%Oper. Margin0.00%ATR (14)1.39Perf 10Y-
Dividend Ex-Date-Quick Ratio4.69Sales Y/Y TTM-Profit Margin0.00%RSI (14)58.53Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.69EPS Q/Q-102.86%SMA203.56%Beta1.39Target Price35.50
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA508.27%Rel Volume1.33Prev Close24.43
Employees74LT Debt/Eq0.09EarningsJul 30SMA20050.33%Avg Volume1.96MPrice24.48
IPO DateNov 15, 2016Option/ShortYes / YesEPS/Sales Surpr.-44.27% -Net Debt/EBITDA1.18Volume2,616,911Change0.20%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedPiper SandlerOverweight$49 → $48
Apr-23-26ReiteratedOppenheimer$25 → $40
Apr-16-26InitiatedStifelBuy$30
Apr-16-26ReiteratedCanaccord GenuityBuy$14 → $38
Apr-10-26InitiatedPiper SandlerOverweight$49
Feb-23-26InitiatedWolfe ResearchOutperform$25
Jan-29-26InitiatedJefferiesBuy$30
Jan-29-26ReiteratedRobert W. Baird$16 → $37
Jan-23-26ReiteratedRBC CapitalOutperform$22 → $36
Oct-13-25InitiatedNeedhamBuy$28
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
8/31/2019
FY 2018
8/31/2018
FY 2017
8/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A013
Gross Profit0-1-3
Selling, General and Administrative Excl. Other493942
Research and Development1186549
Other Operating Expense-1-10
Operating Income-166-104-94
Interest Expense521
Unusual Expense
———
Non-Operating Income (Expense)1222
Net Income Before Taxes-184-109-96
Income Taxes000
Consolidated Net Income-184-109-96
Net Income From Continuing Operations-184-109-96
Net Income-184-109-96
EPS (Recurring)-2.06-1.54-2.44
EPS (Basic, Before Extraordinaries)-2.06-1.54-2.44
EPS (Diluted)-2.06-0.15-2.44
EBITDA-178-106-93
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding897039
Market Capitalization1,192——
Operating Lease Expense
———
Insider Trading Volume
$25.86$23.41$20.95$18.49$16.04● Close Price0.00K199.25K398.50K597.75K797.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karlin DanielChief Medical OfficerMar 25 '26Sale18.478,018148,092413,317Mar 26 12:00 AM
Sullivan MarkChief Legal OfficerMar 25 '26Sale18.4710,702197,666271,079Mar 26 12:00 AM
Barrow RobertChief Executive OfficerMar 25 '26Sale18.4724,431451,241752,454Mar 26 12:00 AM
Karlin DanielChief Medical OfficerDec 26 '25Sale13.155,60073,623425,025Dec 29 12:00 AM
Barrow RobertChief Executive OfficerDec 26 '25Sale13.1525,791339,072778,477Dec 29 12:00 AM
Sullivan MarkChief Legal OfficerDec 26 '25Sale13.1511,276148,244282,576Dec 29 12:00 AM
Sullivan MarkChief Legal OfficerSep 25 '25Sale9.7711,278110,186293,852Sep 26 12:00 AM
Barrow RobertChief Executive OfficerSep 25 '25Sale9.7725,797252,037804,268Sep 26 12:00 AM
Karlin DanielChief Medical OfficerSep 25 '25Sale9.777,70475,268430,625Sep 26 12:00 AM
Sullivan MarkChief Legal OfficerJun 25 '25Sale6.8011,49178,139305,130Jun 26 12:00 AM
Karlin DanielChief Medical OfficerJun 25 '25Sale6.807,84853,366438,329Jun 26 12:00 AM
Barrow RobertChief Executive OfficerJun 25 '25Sale6.8026,491180,139830,065Jun 26 12:00 AM
Barrow RobertChief Executive OfficerMar 25 '25Sale6.7421,208142,942856,556Mar 26 12:00 AM
Karlin DanielChief Medical OfficerMar 25 '25Sale6.746,83646,075446,177Mar 26 12:00 AM
Sullivan MarkChief Legal OfficerMar 25 '25Sale6.746,57644,322316,621Mar 26 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR